Showing results (411-420 of 503) with videos related to
Sort By:
Pageof 51
International Journal of Dermatology|August 21, 2025
Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective StudyLuca Potestio, Cataldo Patruno, Marika Del Gaudio, et al.Nature Genetics|April 2, 2014
Rare missense variants in POT1 predispose to familial cutaneous malignant melanomaJianxin Shi, Xiaohong R Yang, Bari Ballew, et al.Clinical and Experimental Dermatology|October 30, 2025
Psoriasis and Seronegative Spondyloarthropathy in Atopic Dermatitis Patients Treated with Dupilumab or Tralokinumab: A Multicentre Observational StudyGiuseppe Lauletta, Cataldo Patruno, Luca Potestio, et al.BMC Ophthalmology|December 19, 2022
Multidisciplinary ocular and periocular cancers meetings: implementation in a tertiary referral center and analysis over a 12-months periodGustavo Savino, Fabrizio Piccinni, Monica Maria Pagliara, et al.Journal of the European Academy of Dermatology and Venereology : JEADV|October 24, 2025
Pregnancy-associated melanoma epidemiology: A multicentre European studyMaria Kostaki, Michaela Plaka, Vasiliki Chardalia, et al.Oncology Letters|April 14, 2016
Sun exposure and melanoma prognostic factorsSara Gandini, Maurizio Montella, Fabrizio Ayala, et al.Human Vaccines & Immunotherapeutics|April 13, 2021
Immunotherapy and radiotherapy in melanoma: a multidisciplinary comprehensive reviewLuca Tagliaferri, Valentina Lancellotta, Bruno Fionda, et al.Clinical and Experimental Dermatology|June 16, 2025
Psoriasis vulgaris in patients with a recent history of neoplasia: safety of interleukin-23 inhibitors. A multicentre retrospective studyFrancesca Satolli, Silvia Gerosa, Martina Burlando, et al.International Journal of Dermatology|January 5, 2024
Multi-failure psoriasis patients: characterization of the patients and response to biological therapy in a multicenter Italian cohortRiccardo Viola, Luca Mastorino, Matteo Megna, et al.JAMA Dermatology|November 27, 2024
Efficacy and Safety of Nemolizumab in Patients With Moderate to Severe Prurigo Nodularis: The OLYMPIA 1 Randomized Clinical Phase 3 TrialSonja Ständer, Gil Yosipovitch, Franz J Legat, et al.Pageof 51